Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial

Abstract Background The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Method...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2023-01, Vol.227 (2), p.206-210
Main Authors: Huygens, Sammy, Hofsink, Quincy, Nijhof, Inger S, Goorhuis, Abraham, Kater, Arnon P, te Boekhorst, Peter A W, Swaneveld, Francis, Novotný, Věra M J, Bogers, Susanne, Welkers, Matthijs R A, Papageorgiou, Grigorios, Rijnders, Bart J, Heijmans, Jarom
Format: Article
Language:English
Subjects:
COVID-19
COVID-19 Serotherapy
Humans
Immunization, Passive - adverse effects
Immunoglobulins, Intravenous - therapeutic use
SARS-CoV-2
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Methods Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher’s exact test). Conclusions Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available. Anti-SARS-CoV-2 hyperimmune globulin (COVIG) could be a therapy for severely immunocompromised, hospitalized, COVID-19 patients. We performed a randomized, placebo-controlled trial in which a single intravenous infusion with 15 grams of COVIG significantly reduced the progression to severe COVID-19.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiac334